Table 2. Refill and Discontinuation Rates During Follow-up.
| Antihyperglycemic Medication Group | Patient Cohort, No./Total No. (%) | P Valuea | |
|---|---|---|---|
| HDHP | Non-HDHP | ||
| All | |||
| No refills during follow-up period | 103/1490 (6.9) | 97/1490 (6.5) | .80 |
| Discontinuation | |||
| Baseline period | 365/1490 (24.5) | 396/1490 (26.6) | .19 |
| Follow-up period | 255/1125 (22.7) | 255/1094 (23.3) | .72 |
| Branded | |||
| No refills | 81/396 (20.5) | 61/437 (14.0) | .009 |
| Discontinuation | |||
| Baseline period | 105/396 (26.5) | 129/437 (29.5) | .34 |
| Follow-up period | 86/291 (29.6) | 87/308 (28.2) | .72 |
| Generic | |||
| No refills during follow-up period | 117/1405 (8.3) | 125/1367 (9.1) | .45 |
| Discontinuation occurred during | |||
| Baseline period | 377/1405 (26.8) | 396/1367 (29.0) | .21 |
| Follow-up period | 239/1028 (23.2) | 229/971 (23.6) | .86 |
Abbreviation: HDHP, high-deductible health plan.
a
Differences in categorical variables were calculated using χ2 tests; differences in continuous variables, an unpaired t test or analysis of variance with unequal variances and 2-tailed hypothesis.